$5.92
-0.27-4.36%
Last update: Oct 23, 4:00 PM
Solid Biosciences Inc (SLDB) Stock Price, Quote, News & History
SLDBNASDAQ
Solid Biosciences stock fell 8% after new SGT-003 Duchenne trial data. Investors remain cautious despite promising results and FDA plans.
You can purchase shares of Solid Biosciences (NASDAQ:SLDB) through any online brokerage.
Other companies in Solid Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Solid Biosciences has a consensus price target of $18.14.
The stock price for Solid Biosciences (NASDAQ: SLDB) is $5.92 last updated October 23, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Solid Biosciences.
Solid Biosciences does not have any upcoming earnings scheduled.
There is no upcoming split for Solid Biosciences.
Solid Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia,...
